<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564276</url>
  </required_header>
  <id_info>
    <org_study_id>CE 15.114</org_study_id>
    <nct_id>NCT02564276</nct_id>
  </id_info>
  <brief_title>Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer</brief_title>
  <official_title>Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the difference in the proportion of hemipelves with successful detection of
      Sentinel Lymph Node according to the dye used (indocyanine green with near-infrared imaging
      vs blue dye) in women with endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the past few years, Sentinel Lymph Node (SLN) procedure has emerged as an interesting
      solution to the debate on lymphadenectomy in endometrial cancer. Using blue-dye is
      inexpensive but results in an unsatisfactory detection rate of SLN. IndoCyanine Green (ICG)
      with near-infrared imaging is a novel technology for SLN mapping and initial reports on the
      use of ICG have shown high detection rate. In the present study, we aim to determine
      precisely the increase in detection rate of SLN associated with the use of ICG instead of
      blue dye. This randomized controlled trial will include patients with preoperative stage I
      endometrial carcinoma. All included women will undergo SLN mapping with blue dye in one
      hemipelvis and ICG in the other hemipelvis. Randomization will concern the side of the
      hemipelvis in which blue dye vs ICG mapping is used, so that the patient's contralateral
      hemipelvis will serve as a control to her ipsilateral hemipelvis. The primary endpoint is the
      difference in the proportion of hemipelves with successful detection of SLN according to the
      dye used. The unique precise information gained from the present study will contribute to
      determine whether the benefit of the use of ICG over blue dye is sufficient to justify the
      expense of its use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference in the proportion of hemipelves with successful detection of SLN according to the dye used</measure>
    <time_frame>at time of surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Indocyanine Green on the right side</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylene Blue on the right side</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel lymph node biopsy</intervention_name>
    <arm_group_label>Indocyanine Green on the right side</arm_group_label>
    <arm_group_label>Methylene Blue on the right side</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients with endometrial carcinoma proven by endometrial biopsy or curettage AND

          -  preoperative FIGO (International Federation of Gynecology and Obstetrics) stage I AND

          -  intended for staging via laparoscopic or robotic surgery AND

          -  Patients must be older than 18 year-old, able to read French or English.

        Exclusion Criteria:

          -  preoperative FIGO stages II to IV

          -  previous pelvic or paraaortic lymphadenectomy or radiotherapy

          -  surgery that could change the uterine lymphatic drainage (myomectomy)

          -  iodine allergy

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Béatrice Cormier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Montréal Hôpital Saint Luc</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987 Oct 15;60(8 Suppl):2035-41.</citation>
    <PMID>3652025</PMID>
  </results_reference>
  <results_reference>
    <citation>Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, Chi DS, Barakat RR. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol. 2006 Nov;103(2):714-8. Epub 2006 Jun 5.</citation>
    <PMID>16740298</PMID>
  </results_reference>
  <results_reference>
    <citation>Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol. 1987 Aug;94(8):788-90.</citation>
    <PMID>3663535</PMID>
  </results_reference>
  <results_reference>
    <citation>Querleu D, Leblanc E, Cartron G, Narducci F, Ferron G, Martel P. Audit of preoperative and early complications of laparoscopic lymph node dissection in 1000 gynecologic cancer patients. Am J Obstet Gynecol. 2006 Nov;195(5):1287-92. Epub 2006 May 3.</citation>
    <PMID>16677594</PMID>
  </results_reference>
  <results_reference>
    <citation>Barlin JN, Khoury-Collado F, Kim CH, Leitao MM Jr, Chi DS, Sonoda Y, Alektiar K, DeLair DF, Barakat RR, Abu-Rustum NR. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012 Jun;125(3):531-5. doi: 10.1016/j.ygyno.2012.02.021. Epub 2012 Feb 22.</citation>
    <PMID>22366409</PMID>
  </results_reference>
  <results_reference>
    <citation>Desai PH, Hughes P, Tobias DH, Tchabo N, Heller PB, Dise C, Slomovitz BM. Accuracy of robotic sentinel lymph node detection (RSLND) for patients with endometrial cancer (EC). Gynecol Oncol. 2014 Nov;135(2):196-200. doi: 10.1016/j.ygyno.2014.08.032. Epub 2014 Aug 28.</citation>
    <PMID>25175452</PMID>
  </results_reference>
  <results_reference>
    <citation>Cormier B, Rozenholc AT, Gotlieb W, Plante M, Giede C; Communities of Practice (CoP) Group of Society of Gynecologic Oncology of Canada (GOC). Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol. 2015 Aug;138(2):478-85. doi: 10.1016/j.ygyno.2015.05.039. Epub 2015 Jun 3. Review.</citation>
    <PMID>26047592</PMID>
  </results_reference>
  <results_reference>
    <citation>Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Rouzier R, Daraï E. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011 May;12(5):469-76. doi: 10.1016/S1470-2045(11)70070-5. Epub 2011 Apr 12.</citation>
    <PMID>21489874</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indocyanine Green</keyword>
  <keyword>Sentinel Lymph Node Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

